Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 10, 2025, announces positive topline results from the Phase 2a RIVER clinical trial for Haduvio, a drug candidate for the treatment of refractory chronic cough (RCC). The trial was a randomized, double-blind, placebo-controlled, crossover study involving 66 patients.
Key Clinical Metrics and Results
The filing focuses on clinical efficacy and safety data rather than financial metrics. Key results include:
- Primary Endpoint: Haduvio (108 mg BID) achieved a 67% reduction in 24-hour cough frequency from baseline, compared to 10% for placebo. The placebo-adjusted difference was 57% (p<0.0001).
- Subgroup Analysis: Statistically significant reductions were observed in severe cough (66% reduction) and moderate cough (68% reduction) subgroups.
- Responder Rate: 84% of Haduvio patients achieved at least a 30% reduction in cough frequency versus 29% for placebo (55% difference).
- Onset of Action: Statistically significant reductions in cough frequency and improvements in patient-reported outcomes were observed as early as Day 7.
- Safety Profile: Results were consistent with previous trials. Common adverse events included constipation, nausea, somnolence, headache, dizziness, and fatigue. No treatment-emergent serious adverse events were reported.
Material Changes and Outlook
Based on these results, Trevi Therapeutics plans to discuss next steps with the U.S. Food and Drug Administration (FDA). The company anticipates initiating the next study following FDA input. The filing does not provide specific financial guidance, revenue projections, or liquidity updates, as it is a clinical milestone report.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include:
- Uncertainties regarding the success, cost, and timing of future clinical trials.
- The risk that positive Phase 2a data may not predict results in later-stage trials.
- Regulatory uncertainties regarding the FDA's view of the data and the subsequent development path.
Investor Verification Checklist
- Verify the specific design and statistical methodology of the RIVER trial in the full clinical study report.
- Monitor upcoming communications regarding the FDA meeting and the design of the next clinical study.
- Review the company's cash position in the most recent Form 10-Q to assess funding sufficiency for future trials.
- Confirm the safety profile details in the full data readout, particularly regarding dose-dependent adverse events.